Kardigan, Inc. (KARD)
Kardigan, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Princeton, NJ, US. The stock last traded at $18.52, down 0.91% on the session, giving a market capitalisation of $1.65B. On trailing twelve-month figures it carries a trailing P/E of -8.65, a net margin of 0.0%. Its beta of 0.00 implies it has historically moved less than the broad market.
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.